Long-Acting Injectable HIV PrEP PROs

The goal of this observational study is to learn about the real world effectiveness, patient satisfaction and clinical outcomes of LAI PrEP with lenacapavir (LEN) versus cabotegravir (CAB) through surveys and interviews. Participants receiving or initiating LAI PrEP part of their regular medical care will complete surveys and interviews at three study visits over the course of 12 months.

NCT Number	NCT07379658
Lead Sponsor	Anupama Raghuram MD Collaborators: Gilead Sciences, University of Louisville
Conditions	HIV Pre-exposure Prophylaxis
Enrollment	128 participants
Start Date	2026-01-15
Primary Completion	2028-01 (estimated)
Study Completion	2028-01 (estimated)
Updated on ClinicalTrials.gov	2026-01-30